SynthesisThe Cochrane database of systematic reviews2011
Baclofen for alcohol withdrawal.
Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2019Pooled it
- Baclofen for alcohol withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- KASL clinical practice guidelines: management of alcoholic liver disease.Clinical and molecular hepatology · 2013Guideline
- Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.The Cochrane database of systematic reviews · 2011Pooled it
- A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.Biomedical journal · 2016Trial
- Promising strategies for the prevention of alcohol-related brain damage through optimised management of acute alcohol withdrawal: A focussed literature review.Journal of psychopharmacology (Oxford, England) · 2025Review
- Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- Helicobacter pylori's road to colonization.Biomedical journal · 2016Article
- Alcoholic liver disease: treatment.World journal of gastroenterology · 2014Review
- Pharmacological strategies for detoxification.British journal of clinical pharmacology · 2014Review
- GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.Frontiers in neuroscience · 2014Review
- Effects of alcohol on the membrane excitability and synaptic transmission of medium spiny neurons in the nucleus accumbens.Alcohol (Fayetteville, N.Y.) · 2012Review
- Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome.Indian journal of psychiatryArticle
Corrections and comments
- Updated by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easily manageable, what's more, no patient treated with baclofen reported euphoria or other pleasant effects caused by the drug and no subject reported any degree of craving for the drug.
objectivesTo assess the efficacy and safety of baclofen for patients with alcohol withdrawal syndrome. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (September 2010), MEDLINE (1966 to September 2010), EMBASE (1980 to September 2010), and CINAHL (1982 to September 2010). We also searched the following registers of ongoing trials, e.g. Clinicaltrials.gov, Controlled trials.com, EUDRACT, etc. At the same time, we handsearched the references quoted in the identified trials, contact researchers, pharmaceutical companies and relevant trial authors seeking information about unpublished or incomplete trials. All searches included non-English language literature. SELECTION CRITERIA: All randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for patients with AWS. Uncontrolled, non-randomised or quasi-randomised trials were excluded. Both parallel group and cross-over design were included. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN
resultsWe identified a total of 82 references from all electronic databases searched excluding duplicate. After screening of titles and abstracts, full papers of 7 studies were obtained and assessed for eligibility. Finally, only one study met the inclusion criteria, with 37 participants. AUTHORS'
conclusionsThe evidence of recommending baclofen for AWS is insufficient. More well designed RCTs are demanded to further prove its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.